Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6008648 | 0.99 | HSD11B1 (0.32) | MEN1ALDH1A1PKMKMT2AHTR6 | |
| SCHEMBL354787 | 0.86 | KMT2A (0.33) | MEN1KMT2ASLC6A2 | |
| SCHEMBL27686863 | 0.84 | GRIN2D (0.32) | — | |
| SCHEMBL10278489 | 0.83 | MME (0.32) | MEN1ALDH1A1PKMKMT2A | |
| SCHEMBL10277848 | 0.82 | MME (0.32) | CAPN1SLC6A2 | |
| SCHEMBL10232157 | 0.79 | FBP1 (0.34) | ALDH1A1KMT2A | |
| SCHEMBL6008679 | 0.78 | SLC6A2 (0.40) | MEN1KMT2ASLC6A2 | |
| SCHEMBL6009455 | 0.78 | SLC6A2 (0.42) | MEN1KMT2ASLC6A2 | |
| SCHEMBL354580 | 0.76 | SLC6A2 (0.41) | ALDH1A1SLC6A2 | |
| SCHEMBL10278191 | 0.74 | ADRB2 (0.34) | MEN1ALDH1A1PKMKMT2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | MEN1 553/4885ALDH1A1 1915/4885PKM 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.